Agarwal, Rajiv http://orcid.org/0000-0001-8355-7100
Tu, Wanzhu
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01 HL126903)
U.S. Department of Veterans Affairs (I01CX001753)
National Institutes of Health (U24AA026969)
Article History
Received: 15 October 2020
Accepted: 11 February 2021
First Online: 2 March 2021
Declarations
:
: Dr. Agarwal reports personal fees from Relypsa, Inc., a Vifor Pharma Group Company, personal fees from Abbvie, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Celgene, personal fees from Daiichi Sankyo, personal fees from Eli Lilly, personal fees from Gilead, personal fees from Glaxosmithkline, personal fees from Johnson & Johnson, personal fees from Merck, personal fees from Novartis, personal fees from Sandoz, personal fees from ZS Pharma, personal fees from Akebia, personal fees from Takeda, personal fees from Sanofi, personal fees from Reata, personal fees from Ironwood Pharmaceuticals, from Otsuka, from Opko, from Birdrock Bio, outside the submitted work, and Dr. Agarwal has served as an associate editor of the <i>American Journal of Nephrology</i> and <i>Nephrology Dialysis Transplantation</i> and an author on UpToDate and received research grants from the US Veterans Administration and the National Institutes of Health. Dr. Tu has nothing to disclose.
Free to read: This content has been made available to all.